TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06741982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lysogenic HSV virus.
Description: Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 30mg PO QD
Study: NCT06741865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: This arm involves interventions like health coaching, dietary changes, exercise programs, and other lifestyle modifications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Health Education
Description: Participants in the Standard of Care Arm will receive basic educational materials focused on general cognitive and physical health maintenance.
Study: NCT06743386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA)
Description: It will be performed under general anesthesia with intubation, using a sectorial probe echoendoscope to target pancreatic tumors. Prophylactic measures, including intrarectal Diclofenac and antibiotics, are used to prevent complications. A high-frequency monopolar electrode needle is inserted into the lesion under ultrasound guidance, avoiding critical structures like pancreatic and biliary ducts. Energy is delivered until specific safety parameters are met, with multiple applications to maximize tumor coverage. RFA sessions are scheduled before, midway, and after chemotherapy cycles, and progress is monitored with routine imaging. Post-procedure care includes fasting, pain management, and standard blood tests. Patients are typically discharged the day after the procedure if no complications occur. Further treatment plans, including continuation or modification of chemotherapy and RFA, are determined based on disease progression observed in follow-up scans.
Study: NCT05862012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 2001
Description: Participants will receive escalating doses of ISB 2001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 2001
Description: Participants will receive injection of ISB 2001 as determined in Part 1.
Study: NCT04764942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04243044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
Study: NCT05901649

Intervention type: DRUG
Intervention: Apalutamide
Description: No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.

Intervention type: DRUG
Intervention: Enzalutamide
Description: No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
Study: NCT06288373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin：75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
Study: NCT05253443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalizing Imagery Therapy and caregiver skills mobile application
Description: 8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver skills mobile application
Description: 8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
Study: NCT05061719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily
Study: NCT05594095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIK3CA inhibitor
Description: PIK3CA inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKT inhibitor
Description: AKT inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Pd-1 mab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Pd-1 mab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Pd-1 mab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Pd-1 mab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Pd-1 mab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor
Study: NCT06319222

Intervention type: OTHER
Group type: OTHER
Intervention: DALC Digital Clinic
Description: Providers randomized to the intervention arm will be able to refer their patients with ALD, to the DALC in addition to standard of care. Patients with providers randomized to the intervention arm will be consented by the study team. After appropriate consent, the referred patients will be instructed by our study team to download the RTP application in their smart devices (smartphones or tablets).
Study: NCT05594095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: HER2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: HER2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: HER2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: HER2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: HER2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibior
Study: NCT04243044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
Study: NCT06526286

Intervention type: OTHER
Intervention: Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)
Description: Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.
Study: NCT05594095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibior

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibior

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibior

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors or Fulvestrant
Description: Letrozole/Anastrozole/Exemestane or Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors or Fulvestrant
Description: Letrozole/Anastrozole/Exemestane or Fulvestrant
Study: NCT05476796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
Study: NCT05594095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors or Fulvestrant
Description: Letrozole/Anastrozole/Exemestane or Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For premenopause

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For premenopause

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For premenopause

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
Study: NCT05476796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
Study: NCT05594095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: RTK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: TROP2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: TROP2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: TROP2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: NECTIN4 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: NECTIN4 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: HER3 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: HER3 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1167
Description: PARP1i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1167
Description: PARP1i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1167
Description: PARP1i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1167
Description: PARP1i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6209
Description: CDK4i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab
Study: NCT04966104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ODYSSEE-vCHAT
Description: Automated digital counselling program with social network support
Study: NCT06171386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: a form of collagen induction therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization
Study: NCT06514807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (BESREMi®)
Description: Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
Study: NCT06497127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BW-00112
Description: BW-00112 or volume-matched placebo on Day 1 and Day 90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BW-00112
Description: BW-00112 or volume-matched placebo on Day 1 and Day 90
Study: NCT05476796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
Study: NCT06497127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BW-00112
Description: BW-00112 or volume-matched placebo on Day 1 and Day 90
Study: NCT06318130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed helix, lumenless pacing lead.
Description: Patients will be randomised to the fixed helix, lumenless pacing lead design during LBBP implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extendable helix, stylet-driven pacing lead.
Description: Patients will be randomised to the extendable helix, stylet-driven pacing lead design during LBBP implantation.
Study: NCT05432817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
Study: NCT05127057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIME Parkinson Care
Description: A novel model of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual NHS Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual NHS Care
Study: NCT06145282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept
Description: All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept
Description: All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
Study: NCT06278779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine group
Description: The recommended dosing for Spravato is:~Weeks 1-4:~Starting Day 1 dose:~\< 65 years: 56 mg~≥ 65 years: 28 mg~Subsequent doses:~28 mg (≥ 65 years), 56 mg or 84 mg twice weekly~Weeks 5-8:~28 mg (≥ 65 years), 56 mg or 84 mg once weekly~From Week 9:~28 mg (≥ 65 years), 56 mg or 84 mg every 2 weeks or once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic ketamine
Description: Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted as needed using an ascending dose titration schedule:~1. 0.5 mg/kg~2. 0.6 mg/kg~3. 0.75 mg/kg~4. 0.9 mg/kg~5. Further increments by 0.1-0.2 mg/kg, up to max 1.5 mg/kg
Study: NCT06021496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face to face health education
Description: Face-to-face health education with home visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online health education
Description: online health education with video call
Study: NCT05476796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
Study: NCT06026488

Intervention type: OTHER
Intervention: Other
Description: real world treatment and survival of DLBCL patients in China
Study: NCT04880174

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serological testing
Description: Antibody testing for Sars-COV-2 antibodies in blood.
Study: NCT05812508

Intervention type: DEVICE
Intervention: corneal topography
Description: corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft

Intervention type: DEVICE
Intervention: corneal topography
Description: corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
Study: NCT06635629

Intervention type: DRUG
Group type: OTHER
Intervention: Desmopressin
Description: Stimulates ACTH release in Cushing disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Stimulates ACTH release in Cushing disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Stimulates ACTH release in Cushing disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Stimulates ACTH release in Cushing disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Inhibits ACTH release in Cushing disease and healthy volunteers
Study: NCT05388214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Co
Description: The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
Study: NCT05477589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan, cyclophosphamide and melphalan, BuCyMel
Description: a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine, fludarabine and busulfan, CloFluBu
Description: combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
Study: NCT04821375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene plus conjugated estrogens
Description: 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.

Intervention type: DRUG
Group type: OTHER
Intervention: bazedoxifene plus conjugated estrogens
Description: 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
Study: NCT05293041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argipressin
Description: Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.